# Capricor, Inc. – FDA 483, Jul 20, 2026

Source: https://www.keypedia.com/records/483/capricor-inc/7309898f-6112-4937-83de-647a5798d192

> FDA 483 for Capricor, Inc. on July 20, 2026. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Capricor, Inc.
- Inspection Date: 2026-07-20
- Product Type: other
- Office Name: Los Angeles District Office
- Summary: Capricor Inc. in San Diego, CA, received a Form 483 during an FDA inspection for failing to conduct an investigation in accordance with its Investigational New Drug (IND) plan and protocols. The firm demonstrated significant deficiencies, including not following its investigational plan, blinding plan, project management plan, and auditing standard operating procedures. These failures resulted in issues such as unblinded staff having unauthorized access to clinical study data and delayed finalization of audit reports.

## Related Documents

- [483 - 2025-05-30](https://www.keypedia.com/records/483/capricor-inc/1fdac0f1-0869-4652-973d-57941130c486) — date: May 30, 2025
- [CRL](https://www.keypedia.com/records/crl/capricor-inc/bf192b56-c066-4adf-ab8f-6d326c785a2a)
- [483](https://www.keypedia.com/records/483/capricor-inc/abc425b0-aa5d-413e-8813-a61fc7829fe6)

## Related Officers

- [Samson O. Oluseye](https://www.keypedia.com/people/samson-o-oluseye/bfe102f5-25cb-4ed9-9e69-2ec5ec0a047f)

Company: https://www.keypedia.com/companies/capricor-inc/6cf77d9e-08a4-4eca-9918-7f060000bc2a

Office: https://www.keypedia.com/offices/los-angeles-district-office/edcf1dfe-596a-43b8-8df4-07d9cd94763b